Lifeward Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
65.6%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$4.27next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 16 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Quarterly3.9MTarget: Flat full-year revenue compared to 2025 ($22.0M)
Quarterly Operating Cash Burn Quarterly3.7MTarget: Continued reduction through operational efficiencies
ReWalk Personal Exoskeleton Revenue Quarterly1.6MTarget: Growth driven by Medicare reimbursement and international expansion
AlterG Product and Service Revenue Quarterly2.1MTarget: Recovery in Q2 and Q3 2026 as supply chain constraints resolve
Watch Items
- AlterG Supply Chain and Sourcing ConstraintsTrigger: Shipment delays extending past Q3 2026Action: Re-evaluate contract manufacturing transitions and working capital allocation.
- Going Concern Status and Liquidity RunwayTrigger: Unrestricted cash falling below $5.0 million without additional Oramed capital accessAction: Draw down remaining portions of the up to $47 million Oramed partnership capital or implement further cost-reduction measures.
- Nasdaq Listing Compliance (Audit Committee Membership)Trigger: Expiration of the Nasdaq cure period without appointing a third independent directorAction: Expedite the board search and appoint a qualified independent director to satisfy Nasdaq Listing Rule 5605(c)(2)(A).
- ORMD-0801 Oral Insulin Phase 2 Trial InitiationTrigger: Delay in trial commencement beyond late 2026 / early 2027Action: Coordinate with Oramed management to ensure clinical trial activities are funded and executed on schedule.
Research as of 20 Jun 2026